Research programme: stem cell delivery therapies - CellCyte Genetics

Drug Profile

Research programme: stem cell delivery therapies - CellCyte Genetics

Alternative Names: CCG-TH30; CCG-TH35; CCG-TK45; CCG-TL35; CCG-TL40

Latest Information Update: 28 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Department of Veterans Affairs
  • Developer CellCyte Genetics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Kidney disorders; Liver disorders; Lung disorders; Myocardial infarction

Most Recent Events

  • 28 May 2008 CellCyte Genetics signs collaborative agreement with Northwestern University's Feinberg School of Medicine to evaluate CCG-TH30 product in a mouse model of acute myocardial infarction
  • 28 May 2008 Preclinical trials in Myocardial infarction in USA (IV)
  • 11 Sep 2007 Preclinical trials in Kidney disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top